Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 28 of 88 · 4210 articles
People with ulcerative colitis may be interested because the study explores a plant extract that reduced inflammation markers in a common animal model of colitis, suggesting a possible new avenue for drug discovery or...
A decreasing need for IBD-related surgery after pediatric diagnosis could mean fewer major operations and related recovery for children and young adults. It may reflect the growing use of advanced medical therapies in...
A common heart drug, verapamil, reduced disease signs in a mouse model of colitis and altered inflammation and the gut microbiota — suggesting a possible avenue for future IBD research. These are preclinical results, so...
Noninvasive fecal calprotectin levels tracked with endoscopic disease activity in children with colonic Crohn's disease, suggesting FC could help reduce repeat endoscopies and better monitor treatment response.
The study maps layer-specific gene programs in fibrostenotic Crohn's disease and pinpoints the submucosa as a hotspot for fibromuscular remodeling that underlies strictures and bowel obstruction risk.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Anti-TNF. The original article is from hmpgloballearningnetwork.com.
This study identifies reproducible molecular patterns in UC tissue that could help researchers target non-immune pathways (metabolic/mitochondrial) in addition to inflammation, and it highlights that apparently...
Illness perceptions and perceived ability to understand health information are linked to self-care in IBD. If worse illness perceptions tend to lead to later increases in perceived difficulty understanding written...
Cure8 could only read part of this source from newschannel9.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.
The review connects Western diet-driven metabolic shifts in the gut, immune cells, and microbiota to ulcerative colitis mechanisms and highlights metabolism-targeting therapies as a potential future avenue for treatment.
Researchers are studying how proteins from both the host and microbes in the gut relate to Crohn’s disease features. Findings could point to new noninvasive biomarkers or therapeutic strategies to correct dysbiosis,...
This trial represents an early-stage clinical test of a new investigational drug (ATTO-1091) for people with ulcerative colitis; Phase 1 studies establish initial safety and how the drug behaves in the body, which are...
The study aims to map the specific peptide targets of T cells driving organ inflammation in autoimmune diseases, which could guide development of antigen-specific, tolerogenic treatments relevant to Crohn's disease and...
This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could...
Transmural healing may better reflect the full depth of inflammation in Crohn’s disease than mucosal healing alone and is associated with improved long-term outcomes in many studies. If validated and adopted, TH could...
Dietary therapy using the Crohn’s Disease Exclusion Diet plus partial enteral nutrition is an evidence-based nonpharmacologic option for active Crohn’s disease, but adult adherence is often poor. Understanding barriers...
Perianal skin damage from diarrhea (IAD) is common and painful in active Crohn's disease. A combined skin-protection plus individualized nutrition approach was associated with lower IAD rates, less pain, and faster...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Anti-TNF. The original article is from iScience.
The paper identifies a molecular pathway (SERPINB5–MMP9–RLN2) by which the HDAC inhibitor trichostatin A reduced inflammation and protected the intestinal barrier in mouse and cell models of ulcerative colitis,...
Extraintestinal manifestations (skin, joint, eye, liver) are common in IBD and can greatly affect quality of life; better recognition and coordinated care can speed diagnosis and improve outcomes.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis. The original article is from Scandinavian Journal of...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Urgency. The original article is from Gastro hep advances.
Young people with IBD often struggle with health insurance knowledge during transition to adult care. Improving insurance literacy can help them access care and manage coverage decisions. This study suggests a brief,...
GPX and selenium-related pathways may be important to how oxidative stress, ferroptosis, and the microbiome contribute to IBD. Understanding these mechanisms could guide future therapies.
If confirmed, a pathology marker visible on routine biopsy (EGC patterns by SOX10 IHC) could help predict which children with ulcerative colitis are more likely to have improved mucosal inflammation over the first year,...
Based on the title and source metadata, this appears to be a regulatory update related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Immunopharmacology...
If EPS helps restrain inflammation by shifting macrophages toward an M2 phenotype and is reduced in active UC, it could help explain mechanisms of mucosal inflammation and point to new biomarker or therapeutic strategies...
A model that predicts one-year risks for surgery and complications by Montreal phenotype could help identify patients at higher short-term risk and guide research into targeted monitoring or interventions.
CMV colitis can complicate moderate–severe UC flares and—if present—is associated here with longer hospital stays, more frequent escalation to anti‑TNF therapy, and higher colectomy risk.
The paper suggests that the same herbal formula can produce different absorbed components and target interactions depending on oral versus colonic delivery, which could influence therapeutic effects in ulcerative colitis...
Disease-related changes in liver drug-metabolizing enzymes may alter how herbal formulas or medications are processed in people with UC, potentially affecting efficacy or safety. Understanding the mechanisms helps inform...
The study identifies HK2 inhibition as a potential mechanism to shift pro-inflammatory macrophages and reduce intestinal inflammation in preclinical models, which could guide future drug development for IBD.
People with IBD may hear about botanical treatments; this study provides preclinical data that Micromeria imbricata extracts showed beneficial effects in a mouse colitis model and identified compounds that dock to...
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost,...
Fungi in the gut appear to influence immune pathways implicated in IBD and other autoimmune diseases, suggesting new therapeutic targets and microbiome-based interventions that could affect disease activity.
Shifting to patient-initiated, digitally supported follow-up could maintain disease control while reducing routine fixed-interval visits and improving patient experience — relevant as IBD patient numbers grow and clinic...
This paper outlines research strategies aiming to deliver drugs more precisely to inflamed gut tissue and to reshape immune-cell behavior — advances that could eventually lead to safer, more targeted IBD treatments. It’s...
Macrophages are central regulators of intestinal inflammation and repair; understanding their diversity and how to modulate them could lead to new, more targeted treatments for Crohn's disease and ulcerative colitis.
Short periods of extreme heat may modestly increase the chance of hospitalization for IBD and Crohn’s disease. Patients and clinicians should be aware that temperature extremes could be a trigger for worsening disease...
Cure8 found this source from youtube.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Community and awareness. Open the original article for the full details.
Breakfast choices can affect digestion and symptoms for people with Crohn’s. This article offers recipes and practical tips (soluble fiber, cooked fruit, probiotics, lower-lactose options) designed to be easier on the...
Cure8 could only read part of this source from Radiopaedia.org, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring.
If validated, impaired oxalate handling could help explain why some people with IBD react differently to the same plant-rich diet and point to new dietary or microbiome-based interventions to reduce gut inflammation.
The study tests a molecular technique (ATR-FTIR) with machine learning on biopsy tissue to find signals linked to future dysplasia/CRC risk in IBD — a potential complement to colonoscopic surveillance if validated.
Cure8 found this source from wjgnet.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Imaging. Open the original article for the full details.
Researchers and clinicians are watching new oral therapies for patients whose disease has failed biologic treatments. If supported by full data, a safe, oral drug that helps refractory Crohn’s disease and ulcerative...
This hire signals Coultreon is prioritizing commercial and development work on its SIK3 inhibitor COL-5671, which the company highlights as a potential oral treatment relevant to ulcerative colitis and Crohn’s disease.
